FDA Approves Orzeyful (Oveporexton) for Narcolepsy Type 1 Symptoms
The U.S. Food and Drug Administration (U.S. FDA) has approved Orzeyful (oveporexton) tablets, manufactured by Takeda Pharmaceuticals, to treat narcolepsy type 1 (NT1) in adults. The FDA describes it as the first therapeutic drug approved for narcolepsy type 1 as a complete disorder — addressing the full range of symptoms that define the condition — and the first to work by directly targeting the loss of orexin signaling that causes the disease. FDA
Why This Approval Matters:
Existing narcolepsy type 1 therapies, including stimulants and sedatives, have only managed individual symptoms without addressing the underlying orexin deficiency that drives the disorder. Oveporexton is the first agent to activate the OX2R receptor directly, restoring the signal that is lost when orexin-producing neurons are destroyed. HCP Live
Narcolepsy type 1 occurs when the brain loses certain cells that produce a chemical called orexin, which helps control sleep and wake cycles. Without enough orexin, the brain struggles to stay awake and to separate sleeping and waking periods. NT1 is a rare, lifelong neuropsychiatric sleep disorder that affects an estimated 1 in 2,000 people in the United States. Pharmacy Times
Tiffany R. Farchione, M.D., Director of the Division of Psychiatry within the FDA's Center for Drug Evaluation and Research, framed the approval as overdue relief for patients who have long relied on piecemeal treatment.
How the Drug Works
Orzeyful is an oral orexin receptor 2 (OX2R) agonist designed to selectively stimulate the OX2R to restore signaling and address the underlying orexin deficiency associated with narcolepsy type 1. Stanford sleep medicine researcher Dr. Emmanuel Mignot, the principal U.S. investigator on the drug's Phase 3 program, noted that prior treatment approaches only managed symptoms rather than the disease itself. CheckRare
Clinical Trial Results:
The approval rests on a comprehensive clinical program including the global Phase 3 FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002) studies, which showed statistically significant improvements across the full range of NT1 symptoms — including excessive daytime sleepiness, cataplexy, and health-related quality of life.
The FDA's approval was based on two 12-week clinical trials involving 273 adults with narcolepsy type 1, comparing the drug against placebo. To measure wakefulness, participants were asked to sit in a dark, quiet room for 40-minute sessions and try to stay awake as long as possible. Patients taking Orzeyful stayed awake 12 to 19 minutes longer than they had before starting the medicine — a marked improvement compared with the placebo group, who stayed awake about a minute less than before starting treatment. WebMD
Oveporexton also produced significant improvements on the Narcolepsy Severity Scale for Clinical Trials and Patient Global Impression of Change scores at week 12. Pulmonology Advisor
Safety Profile:
The most commonly reported side effects were insomnia, urinary urgency and frequency, and excessive salivation, with the drug's safety profile remaining consistent across the clinical program. The prescribing information also carries a warning regarding elevated creatine phosphokinase levels. Oveporexton should not be co-administered with strong CYP3A inhibitors, and its safety and effectiveness have not been established in patients under 18. PharmExecPulmonology Advisor
What Comes Next:
The drug is not yet available to patients. It has been recommended for scheduling under the Controlled Substances Act and requires a formal DEA scheduling decision before it can be marketed. That classification review is expected to conclude within 90 days, after which the treatment will likely be distributed through specialty pharmacies. Takeda has said it is advancing U.S. launch preparations and expects to make Orzeyful available once the DEA process is complete.
Orzeyful was previously approved in China before receiving this U.S. clearance. Takeda CEO Julie Kim called the approval the start of a new chapter for the NT1 community, describing the drug as an entirely new class of medicine with the potential to change how the disease is managed and how patients feel while on treatment.
